Novelos touts promising initial results for agent LIGHT

04/26/2012 | Yahoo!

Novelos Therapeutics said the University of Wisconsin Carbone Cancer Center has finished the first cohort in a Phase I/II trial involving I-124-CLR1404, its PET imaging agent for cancer that is being tested on patients with advanced non-small cell lung cancer. Initial study results indicate the agent, also called LIGHT, can identify tumors more accurately than 18F-fluorodeoxyglucose, a researcher said.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC